Cargando…
Prevalence and Impact Factors of COVID-19 Vaccination Hesitancy Among Breast Cancer Survivors: A Multicenter Cross-Sectional Study in China
Cancer patients are at a high risk of being infected with COVID-19 and have a poor prognosis after infection. Breast cancer is one of the most common cancers. Since vaccination is an effective measure to prevent the spread of COVID-19, we studied the vaccination rate among breast cancer survivors an...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595240/ https://www.ncbi.nlm.nih.gov/pubmed/34805207 http://dx.doi.org/10.3389/fmed.2021.741204 |
_version_ | 1784600155939405824 |
---|---|
author | Peng, Xin Gao, Ping Wang, Qiong Wu, Hong-ge Yan, Yun-li Xia, Ying Wang, Jian-ying Lu, Fang Pan, Hong Yang, Yi Liang, Fan Zhao, Lei Cheng, Jing |
author_facet | Peng, Xin Gao, Ping Wang, Qiong Wu, Hong-ge Yan, Yun-li Xia, Ying Wang, Jian-ying Lu, Fang Pan, Hong Yang, Yi Liang, Fan Zhao, Lei Cheng, Jing |
author_sort | Peng, Xin |
collection | PubMed |
description | Cancer patients are at a high risk of being infected with COVID-19 and have a poor prognosis after infection. Breast cancer is one of the most common cancers. Since vaccination is an effective measure to prevent the spread of COVID-19, we studied the vaccination rate among breast cancer survivors and analyzed their characteristics to provide evidence for boosting the vaccination rate. The researchers conducted a multicenter, cross-sectional study on 747 breast cancer survivors from six hospitals in Wuhan city between June 5, 2021, and June 12, 2021. The self-administrated questionnaires based on relevant studies were distributed. The researchers then compared differences in characteristics among vaccinated patients, hesitant patients, and non-vaccinated patients. Moreover, they performed univariable and multivariable logistic regression analyses to identify potential factors associated with vaccination hesitancy. The researchers assessed a total of 744 breast cancer survivors −94 cases in the vaccinated group, 103 in the planning group, 295 in the hesitancy group, and 252 in the refusal group. The vaccination rate was 12.63% (95% CI 10.25–15.02%) and 37.23% (95% CI 27.48–47.82%) patients reported adverse reactions. The vaccination hesitancy/refusal rate was 73.52% (95% CI 70.19–76.66%), which was independently associated with current endocrine or targeted therapy (odds ratio [OR] = 1.52, 95% CI 1.03–2.24), no notification from communities or units (OR = 2.46, 95% CI 1.69–3.59) and self-perceived feel (general vs. good, OR = 1.46, 95% CI 1.01–2.13; bad vs. good, OR = 4.75, 95% CI 1.85–12.16). In the hesitancy/refusal group, the primary reason was “I did not know who to ask whether I can get vaccinated” (46.07%), the person who would most influence decisions of patients was the doctor in charge of treatment (35.83%). Effective interaction between doctors and patients, simple and consistent practical guidelines on vaccination, and timely and positive information from authoritative media could combat misinformation and greatly reduce vaccine hesitancy among breast cancer survivors. |
format | Online Article Text |
id | pubmed-8595240 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85952402021-11-18 Prevalence and Impact Factors of COVID-19 Vaccination Hesitancy Among Breast Cancer Survivors: A Multicenter Cross-Sectional Study in China Peng, Xin Gao, Ping Wang, Qiong Wu, Hong-ge Yan, Yun-li Xia, Ying Wang, Jian-ying Lu, Fang Pan, Hong Yang, Yi Liang, Fan Zhao, Lei Cheng, Jing Front Med (Lausanne) Medicine Cancer patients are at a high risk of being infected with COVID-19 and have a poor prognosis after infection. Breast cancer is one of the most common cancers. Since vaccination is an effective measure to prevent the spread of COVID-19, we studied the vaccination rate among breast cancer survivors and analyzed their characteristics to provide evidence for boosting the vaccination rate. The researchers conducted a multicenter, cross-sectional study on 747 breast cancer survivors from six hospitals in Wuhan city between June 5, 2021, and June 12, 2021. The self-administrated questionnaires based on relevant studies were distributed. The researchers then compared differences in characteristics among vaccinated patients, hesitant patients, and non-vaccinated patients. Moreover, they performed univariable and multivariable logistic regression analyses to identify potential factors associated with vaccination hesitancy. The researchers assessed a total of 744 breast cancer survivors −94 cases in the vaccinated group, 103 in the planning group, 295 in the hesitancy group, and 252 in the refusal group. The vaccination rate was 12.63% (95% CI 10.25–15.02%) and 37.23% (95% CI 27.48–47.82%) patients reported adverse reactions. The vaccination hesitancy/refusal rate was 73.52% (95% CI 70.19–76.66%), which was independently associated with current endocrine or targeted therapy (odds ratio [OR] = 1.52, 95% CI 1.03–2.24), no notification from communities or units (OR = 2.46, 95% CI 1.69–3.59) and self-perceived feel (general vs. good, OR = 1.46, 95% CI 1.01–2.13; bad vs. good, OR = 4.75, 95% CI 1.85–12.16). In the hesitancy/refusal group, the primary reason was “I did not know who to ask whether I can get vaccinated” (46.07%), the person who would most influence decisions of patients was the doctor in charge of treatment (35.83%). Effective interaction between doctors and patients, simple and consistent practical guidelines on vaccination, and timely and positive information from authoritative media could combat misinformation and greatly reduce vaccine hesitancy among breast cancer survivors. Frontiers Media S.A. 2021-11-03 /pmc/articles/PMC8595240/ /pubmed/34805207 http://dx.doi.org/10.3389/fmed.2021.741204 Text en Copyright © 2021 Peng, Gao, Wang, Wu, Yan, Xia, Wang, Lu, Pan, Yang, Liang, Zhao and Cheng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Peng, Xin Gao, Ping Wang, Qiong Wu, Hong-ge Yan, Yun-li Xia, Ying Wang, Jian-ying Lu, Fang Pan, Hong Yang, Yi Liang, Fan Zhao, Lei Cheng, Jing Prevalence and Impact Factors of COVID-19 Vaccination Hesitancy Among Breast Cancer Survivors: A Multicenter Cross-Sectional Study in China |
title | Prevalence and Impact Factors of COVID-19 Vaccination Hesitancy Among Breast Cancer Survivors: A Multicenter Cross-Sectional Study in China |
title_full | Prevalence and Impact Factors of COVID-19 Vaccination Hesitancy Among Breast Cancer Survivors: A Multicenter Cross-Sectional Study in China |
title_fullStr | Prevalence and Impact Factors of COVID-19 Vaccination Hesitancy Among Breast Cancer Survivors: A Multicenter Cross-Sectional Study in China |
title_full_unstemmed | Prevalence and Impact Factors of COVID-19 Vaccination Hesitancy Among Breast Cancer Survivors: A Multicenter Cross-Sectional Study in China |
title_short | Prevalence and Impact Factors of COVID-19 Vaccination Hesitancy Among Breast Cancer Survivors: A Multicenter Cross-Sectional Study in China |
title_sort | prevalence and impact factors of covid-19 vaccination hesitancy among breast cancer survivors: a multicenter cross-sectional study in china |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595240/ https://www.ncbi.nlm.nih.gov/pubmed/34805207 http://dx.doi.org/10.3389/fmed.2021.741204 |
work_keys_str_mv | AT pengxin prevalenceandimpactfactorsofcovid19vaccinationhesitancyamongbreastcancersurvivorsamulticentercrosssectionalstudyinchina AT gaoping prevalenceandimpactfactorsofcovid19vaccinationhesitancyamongbreastcancersurvivorsamulticentercrosssectionalstudyinchina AT wangqiong prevalenceandimpactfactorsofcovid19vaccinationhesitancyamongbreastcancersurvivorsamulticentercrosssectionalstudyinchina AT wuhongge prevalenceandimpactfactorsofcovid19vaccinationhesitancyamongbreastcancersurvivorsamulticentercrosssectionalstudyinchina AT yanyunli prevalenceandimpactfactorsofcovid19vaccinationhesitancyamongbreastcancersurvivorsamulticentercrosssectionalstudyinchina AT xiaying prevalenceandimpactfactorsofcovid19vaccinationhesitancyamongbreastcancersurvivorsamulticentercrosssectionalstudyinchina AT wangjianying prevalenceandimpactfactorsofcovid19vaccinationhesitancyamongbreastcancersurvivorsamulticentercrosssectionalstudyinchina AT lufang prevalenceandimpactfactorsofcovid19vaccinationhesitancyamongbreastcancersurvivorsamulticentercrosssectionalstudyinchina AT panhong prevalenceandimpactfactorsofcovid19vaccinationhesitancyamongbreastcancersurvivorsamulticentercrosssectionalstudyinchina AT yangyi prevalenceandimpactfactorsofcovid19vaccinationhesitancyamongbreastcancersurvivorsamulticentercrosssectionalstudyinchina AT liangfan prevalenceandimpactfactorsofcovid19vaccinationhesitancyamongbreastcancersurvivorsamulticentercrosssectionalstudyinchina AT zhaolei prevalenceandimpactfactorsofcovid19vaccinationhesitancyamongbreastcancersurvivorsamulticentercrosssectionalstudyinchina AT chengjing prevalenceandimpactfactorsofcovid19vaccinationhesitancyamongbreastcancersurvivorsamulticentercrosssectionalstudyinchina |